Back to Annual Meeting

Back to Annual Meeting

APHA Scientific Session and Event Listing

Aruna V. Sarma, PhD¹, Lauren P. Wallner, MPH¹, Stephanie Daignault, MS², and John T. Wei, MD, MS¹. (1) Department of Urology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, 734-763-7514, asarma@umich.edu, (2) Cancer Center, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-0473

Introduction: Both metabolic syndrome and prostate cancer are significant causes of morbidity and mortality among men in the U.S. Previous work has suggested that components of metabolic syndrome are individually associated with prostate cancer risk. The objective of this study was to examine the association between the components of metabolic syndrome and self-reported prostate cancer in a national sample using data from the most recent National Health and Nutrition Examination Survey (NHANES). Methods: NHANES 2001-2002 is a sample of non-institutionalized US residents 2 months and older. Included in this analysis were 1551 men ages 40 years and older, who were not missing data on metabolic syndrome components and prostate cancer questions. Analyses accounted for multistage sampling and probability weights. Results: Of the 81 cases of prostate cancer, 34.6% were classified as having metabolic syndrome defined as having 3 of 5 specific components compared to 25.9% of the 1470 disease-free controls (p=0.001) High blood pressure and having at least 3 or more components of metabolic syndrome were found to be significantly associated with prostate cancer risk. Conclusion: In this population-based sample of US men, we observed that specific features of metabolic syndrome, specifically high blood pressure, were more common in prostate cancer cases than disease-free controls. These initial prevalence estimates are consistent with recent studies which have reported a possible relationship between hypertension and prostate cancer and suggest high blood pressure may be a marker for increased central sympathetic nervous activity which may result in androgen-mediated stimulation of prostate cancer growth.

Learning Objectives: At the conclusion of this session, the participant in this session will be able to

• Describe more comprehensively the relationship between metabolic syndrome and prostate cancer in men.
• Identify that multiple components of metabolic syndrome, such as hypertension, are more common in men with prostate cancer compared to disease-free controls.
• Develop future research to determine possible mechanisms, prevention strategies, and treatment outcomes among men with features of the metabolic syndrome and prostate cancer.

Keywords: Cancer, Diabetes

Presenting author's disclosure statement:

Any relevant financial relationships? No